Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple …; Sacituzumab govitecan in metastatic triple-negative breast cancer; Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program; A single-cell map of intratumoral changes during anti-PD1 treatment of patients with breast cancer; Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer; LBA17 ASCENT: a randomized phase III study of sacituzumab govitecan (SG) vs treatment of physician’s choice (TPC) in patients (pts) with previously treated metastatic triple …; Impact of solid cancer on in-hospital mortality overall and among different subgroups of patients with COVID-19: a nationwide, population-based analysis; Incidence of osteonecrosis of the jaw in patients with bone metastases treated sequentially with bisphosphonates and denosumab; Incidence of medication-related osteonecrosis of the jaw in patients treated with both bone resorption inhibitors and vascular endothelial growth factor receptor tyrosine …; Mortality in adult patients with solid or hematological malignancies and SARS-CoV-2 infection with a specific focus on lung and breast cancers: A systematic review and meta …; The impact of COVID-19 on oncology professionals: results of the ESMO Resilience Task Force survey collaboration; Abstract PD13-07: Subgroup analysis of patients with brain metastases from the phase 3 ASCENT study of sacituzumab govitecan versus chemotherapy in metastatic triple-negative …; Body mass index and tumor-infiltrating lymphocytes in triple-negative breast cancer; A network analysis to identify mediators of germline-driven differences in breast cancer prognosis; Transcriptome‐wide association study of breast cancer risk by estrogen‐receptor status; The FANCM: p. Arg658* truncating variant is associated with risk of triple-negative breast cancer; Secondary prevention in hereditary breast and/or ovarian cancer syndromes other than BRCA; Behavior of metastatic breast cancer according to subtype; Emerging therapeutics for patients with triple-negative breast cancer; Abstract GS3-06: Biomarker evaluation in the phase 3 ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer
